secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2025-05-22T23:59:59+00:00
Accession:  0001104659-25-051841
Event type: m_and_a
Sentiment:  negative
Materiality: 0.95
Item codes: 1.01, 1.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA to sell HB-400/HB-500 assets to Gilead for up to $10M; board approves dissolution
--------------------------------------------------------------------------------

- Gilead to acquire HB-400 and HB-500 assets for up to $10M in cash; $3M at closing, up to $7M in transfer completion payments.
- Board approved dissolution of HOOKIPA; filing of Certificate of Dissolution expected after Transfer Plan completion.
- Asset sale and dissolution require stockholder approval; proxy statement to be filed for special meeting.
- CEO Malte Peters receives severance, accelerated equity vesting, and a Special Dissolution Success Bonus up to €482,591.
- Collaboration Agreement and Stock Purchase Agreement with Gilead will terminate at closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000110465925051841/0001104659-25-051841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000110465925051841/tm2515845d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-051841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer